Targeting of SRC-3 in immune cells as an immunomodulatory therapeutic for the treatment of cancer
NZ836415APending Publication Date: 2026-08-28BAYLOR COLLEGE OF MEDICINE
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- NZ836415
- Authority / Receiving Office
- NZ · NZ
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-10-28
- Filing Date
- 2021-08-27
- Publication Date
- 2026-08-28
Smart Images
Figure 00000041_0000 
Figure 00000042_0000 
Figure 00000043_0000
Abstract
The present disclosure concerns methods and compositions related to cancer treatment comprising targeting of SRC-3 in immune cells, including T cells such as T regulatory cells. The targeting of SRC-3 in T regulatory cells in particular is effective to eradicate tumors in mammals. In specific cases, the T regulatory cells are subjected to CRISPR ex vivo to produce cells suitable for adoptive cell transfer. In some cases, one or more agents that target SRC-3 are also administered to the individual and / or are exposed to the cells prior to administration.
Need to check novelty before this filing date? Find Prior Art